

PROGRAM



5th European Myeloma Network Meeting



Turin

April 18-20, 2024

Lingotto Conference Center

REQUESTED AUSPICES

UNIVERSITÀ DI TORINO

A.O.U. - Città della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare

AIL - Associazione Italiana contro le Leucemie-linfomi e mieloma Onlus

ASSOMONITOR - Associazione Italiana dei Clinical Monitors

WELCOME MESSAGE

Dear colleagues and friends,

It is our great pleasure to invite you to attend the 5th EMN meeting – EMN2024 - that will take place in Turin, Italy - from 18 to 20 April 2024.

Last year, we had a very fruitful and successful meeting in Amsterdam, and we were extremely happy to meet everyone in person again, after some editions held virtually. Now we cannot wait to welcome you to the majestic and elegant city of Turin in 2024.

The EMN2024 will be a unique opportunity for anyone working in the myeloma field to be informed of the latest developments and most innovative treatments for myeloma patients. New, effective clinical trials will be presented during interactive and lively sessions, with expert speakers from all over the world. The EMN2024 will be a highly formative and educational event, particularly for young researchers, and also for nurses, data managers and study coordinators.

Also in this edition, patients' associations will play a central role. We aim to dedicate a special session to know their perspective and expectations, and to consider their valuable suggestions for future studies. As an inclusive and open network, the EMN is also committed to continuing and strengthening the collaboration with various national research groups, with key scientific societies – particularly, the European Hematology Association - and companies promoting new and effective clinical trials. We are always grateful for their valuable contribution and support.

The location of the EMN2024 meeting will be the Lingotto Conference Center, an ideal venue to host important international conferences and big events in Turin. The venue is very well connected to the rest of the city, which will allow you to enjoy the conference and also visit Turin, Italy's first capital, with its stunning architecture, multicultural environment, innovative present and regal past.

We look forward to welcoming you soon!

Mario Boccardo & Pieter Sonneveld

On behalf of the Scientific organizers, Program Coordinators and the EMN Board.

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld (*The Netherlands*) - EMN President

Mario Boccardo (*Italy*) - EMN Vicepresident

Francesca Gay (*Italy*)

Roberto Mina (*Italy*)

Niels van de Donk (*The Netherlands*)

Sonja Zweegman (*The Netherlands*)

FACULTY

Nizar Jacques	Bahlis	Calgary, Canada	Suzanne	Lentzsch	New York, USA
Angelo	Belotti	Brescia, Italy	Heinz	Ludwig	Wien, Austria
Mario	Boccardo	Turin, Italy	Elias K.	Mai	Heidelberg, Germany
Niccolò	Bolli	Milan, Italy	Salomon	Manier	Lille, France
Ivan Marques	Borrello	Baltimore, USA	Hira	Mian	Hamilton, Canada
Sara	Bringhen	Turin, Italy	Paolo	Milani	Pavia, Italy
Annemiek	Broijl	Rotterdam, The Netherlands	Roberto	Mina	Turin, Italy
Benedetto	Bruno	Turin, Italy	Mohamad	Mohty	Paris, France
Gastone	Castellani	Bologna, Italy	Vittorio	Montefusco	Milan, Italy
Michele	Cavo	Bologna, Italy	Adrian	Mosquera Orgueira	Santiago de Compostela, Spain
Guldane	Cengiz-Seval	Ankara, Turkey	Pellegrino	Musto	Bari, Italy
Thomas	Cupedo	Amsterdam, The Netherlands	Paola	Neri	Calgary, Canada
Mattia	D'Agostino	Turin, Italy	Giovanni	Palladini	Pavia, Italy
Michel	Delforge	Leuven, Belgium	Charlotte	Pawlyn	London, United Kingdom
Meletios-Athanasios	Dimopoulos	Athens, Greece	Rakesh	Popat	London, United Kingdom
Angela	Dispenzieri	Rochester, USA	Marc	Raab	Heidelberg, Germany
Christoph	Driessen	St. Gallen, Switzerland	Jakub	Radocha	Hradec Kralove, Czech Republic
Brian G.M.	Durie	Los Angeles, USA	Karthik	Ramasamy	Oxford, United Kingdom
Hermann	Einsele	Würzburg, Germany	Paula	Rodríguez Otero	Pamplona, Spain
Thierry	Facon	Lille, France	Laura	Rosinol Dachs	Barcelona, Spain
Carlos Jose	Fernandez De Larrea Rodriguez	Barcelona, Spain	Vaishali	Sanchorawala	Boston, USA
Alfred	Garfall	Philadelphia, USA	Tobias Schmidt	Slørdahl	Trondheim, Norway
Francesca Maria	Gay	Turin, Italy	Pieter	Sonneveld	Rotterdam, The Netherlands
Irene M.	Ghobrial	Boston, USA	Andrew	Spencer	Clayton, Australia
Nicola	Giuliani	Parma, Italy	Edward A.	Stadtmauer	Philadelphia, USA
Kazimierz	Groen	Amsterdam, The Netherlands	Claudia A.M.	Stege	Amsterdam, The Netherlands
Roman	Hájek	Ostrava, Czech Republic	Evangelos	Terpos	Athens, Greece
Hans	Jacobs	Nijmegen, The Netherlands	Cyrille	Touzeau	Nantes, France
Andrzej Jozef	Jakubowiak	Chicago, USA	Saad Z.	Usmani	Charlotte, USA
Katie	Joyner	Brussels, Belgium	Niels	van de Donk	Amsterdam, The Netherlands
Martin	Kaiser	London, United Kingdom	Johannes	Waldschmidt	Würzburg, Germany
Efstathios	Kastritis	Athens, Greece	Katja Christina	Weisel	Hamburg, Germany
Maria Theresa	Krauth	Wein, Austria	Kwee	Yong	London, United Kingdom
Alessandra	Larocca	Turin, Italy	Elena	Zamagni	Bologna, Italy
Xavier	Leleu	Poitiers Cedex, France	Sonja	Zweegman	Amsterdam, The Netherlands

TIMETABLE

Thursday, April 18, 2024	Friday, April 19, 2024	Saturday, April 20, 2024
		09.00 - 09.30 MENARINI STEMLINE SPONSORED LECTURE
09.25 - 09.30 OPENING CEREMONY	09.00 - 09.45 SESSION V NDMM - TRANSPLANT-ELIGIBLE PATIENTS	09.30 - 10.30 SESSION X CHALLENGE SESSION - INNOVATION AND CHALLENGES IN MM
09.30 - 10.50 SESSION I MGUS AND SMM	09.45 - 10.50 SESSION VI RRMM PATIENTS	10.30 - 11.25 SESSION XI AMYLOIDOSIS
10.50 - 11.10 COFFEE BREAK AND POSTER VIEWING	10.50 - 11.15 COFFEE BREAK AND POSTER VIEWING	11.25 - 11.40 COFFEE BREAK AND POSTER VIEWING
11.10 - 12.20 SESSION II RISK STRATIFICATION	11.15 - 12.15 SESSION VII IMMUNOTHERAPY	11.40 - 12.40 SESSION XII EHA - EMN JOINT SESSION
12.20 - 13.30 SESSION III MRD IN CLINICAL TRIALS AND APPLICATION CHALLENGES IN CLINICAL PRACTICE	12.15 - 13.15 SESSION VIII BREAKTHROUGH TRIALS CHANGING CLINICAL PRACTICE	12.40 - 13.20 SESSION XIII RESHAPING THE FUTURE: THE TRIALS THAT WE NEED
13.30 - 14.30 LUNCH AND MEET THE EXPERT SESSION	13.15 - 14.15 LUNCH AND MEET THE EXPERT SESSION	13.20 - 14.00 LUNCH AND POSTER VIEWING
14.30 - 15.30 SESSION IV NDMM - TRANSPLANT-INELIGIBLE PATIENTS	14.15 - 15.00 SESSION IX HARMONY ALLIANCE: DATA-DRIVEN RESEARCH IN MULTIPLE MYELOMA	14.00 - 14.40 SESSION XIV PATIENTS ASSOCIATIONS
15.30 - 15.50 COFFEE BREAK AND POSTER VIEWING	15.00 - 15.30 COFFEE BREAK AND POSTER VIEWING	14.40 - 15.25 SESSION XV TOXICITY OF IMMUNOTHERAPY
15.50 - 17.20 BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM	15.30 - 17.00 JOHNSON & JOHNSON SPONSORED SYMPOSIUM	15.25 - 15.30 CONCLUSIONS AND FINAL GREETINGS
17.20 - 18.50 INDEPENDENT MEDICAL EDUCATIONAL SESSION - UNCONDITIONAL SUPPORT BY GSK	17.00 - 18.30 PER SYMPOSIUM - UNCONDITIONAL SUPPORT BY SANOFI	
19.00 - 20.00 WELCOME COCKTAIL		

CONGRESS INFORMATION

VENUE

LINGOTTO CONFERENCE CENTER

Via Nizza, 280 - 10126 Turin - Italy
Ph +39 011 6311702
www.centrocongressilingotto.it

HOW TO REACH THE LINGOTTO CONFERENCE CENTER

The Lingotto Conference Centre is 10 minutes from the center of Turin. Various buses run in the city center and will take you close to the Lingotto Conference Center. In particular, you can use the metro to both attend the conference and visit the city. Turin has only one Metro line (M1), and metro stops are indicated with a white M on a red background. A metro stop (Lingotto stop) is located right in front of the Lingotto Conference Center.

You can buy either a single-ride ticket (City100 - valid for 100 minutes once you pass the turnstile) or a daily pass (the most convenient option if you wish to visit the city center after the conference).

More details about Turin public transports can be found at <https://www.gtt.to.it/cms/en/>

Turin also has three main train stations: Torino Porta Susa, Torino Porta Nuova, and Torino Lingotto. Both Torino Porta Susa and Torino Porta Nuova have a metro stop inside or closeby the train station. Further instructions on how to reach the Lingotto Conference Center from these train stations are reported below.

Participants arriving from motorways or from city by-pass roads can follow the road signs to go directly to the Lingotto underground car parks.

From Turin Airport - Torino Aeroporto di Caselle: Turin Airport (also known as Torino Aeroporto di Caselle or Sandro Pertini Airport) is 16 km away from the city center and can be reached in about 30-35 minutes by taxi, at a fixed rate.

Trains are also available from the airport and they run every 30 minutes.

At the Arrivals floor (floor zero), exit the building and walk through the car rental area in the parking lot. You can buy a single-ride ticket at the machines after the car rental, or directly through the website <https://www.trenitalia.com/en.html> - select "Torino Aeroporto di Caselle" as your departure station, and "Torino Porta Susa" as your destination. Once on the train, (approx. ride duration: 30 minutes) you can get off at Torino Porta Susa station and take the metro to Lingotto stop (direction "Bengasi", 9 stops). The metro stop is inside the train station, you do not need to exit. Metro tickets can be bought at the machines in front of the metro turnstiles, and you can buy either a single-ride ticket (City100) or a daily pass.

From Porta Susa train station: take the metro to Lingotto stop (direction "Bengasi", 9 stops). The metro stop is inside the train station, you do not need to exit. Metro tickets can be bought at the machines in front of the metro turnstiles, and you can buy either a single-ride ticket (City100) or a daily pass.

From Porta Nuova train station: take the metro to Lingotto stop (direction "Bengasi", 6 stops). You can reach the metro stop either through the escalator in the main hall of the station; or you can exit the station in Corso Vittorio Emanuele and walk down the stairs or take the elevator to the metro stop. Metro tickets can be bought at the machines in front of the metro turnstiles, and you can buy either a single-ride ticket (City100) or a daily pass.

From Lingotto train station: take the underpass inside the train station, heading to Italia 61/ Regione Piemonte skyscraper. Once you are out of the underpass, walk towards the Regione Piemonte skyscraper - you will see a covered path in front of you, a red and white structure with red benches on the way. Walk to the end of that path, you will see a metro stop in front of you and the skyscraper to your right. You can either take the underground metro and get off at Lingotto stop (direction "Fermi", one stop only) - metro tickets can be bought at the machines in the underground metro stop, right in front of the metro turnstiles, and you can buy either a single-ride ticket (City100) or a daily pass. Or, if you would rather walk and not take the metro, just turn left in via Nizza and walk for about 10 minutes. The Lingotto Conference Center will be on your left.

By Car: from the main motorways Piacenza, Pavia, Genova, Savona, Milano, Aosta Frejus e Pinerolo - direction TORINO, continue on the South Ringroad - exit Corso Unità d'Italia then follow signs to Lingotto; from downtown: access to the underground paying car parking - entrance in Via Nizza n. 230 and n. 280 bis.

Pedestrian entrance: Via Nizza n. 280

REGISTRATION FEES

Registration Categories	Earlybird online registration until 5 April	After 5 April and onsite registration
Standard*	€ 400,00	€ 500,00
Participants under 35 years	€ 250,00	€ 350,00
Nurses and Data Managers	€ 200,00	€ 300,00
Exhibitors**	€ 150,00	€ 250,00

To avoid long lines at the on-site registration counters, we encourage you to register for the meeting in advance.

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition and poster areas
- Conference kit
- Certificate of attendance
- Lunches
- Coffee breaks
- Welcome cocktail

* Sponsor staff members who have registered with a standard fee can have access to the scientific session sitting in a dedicated area.

** Exhibitor fee DOES NOT include: conference kit, participation in the scientific sessions.

REGISTRATION HOURS

Individuals and Exhibitors	
Wednesday, April 17, 2024	17.00 - 19.00
Thursday, April 18, 2024	08.00 - 18.00
Friday, April 19, 2024	08.00 - 18.00
Saturday, April 20, 2024	08.00 - 12.00
Groups	
Wednesday, April 17, 2024	15.00 - 19.00

REGISTRATION BADGES

Badges and meeting materials will be given at the counters in the registration area.

Remember to print prior and to bring with you the invitation letter and the badge QRcode you received in the "Registration Info" automatic e-mail.

All registered participants, speakers, sponsors and exhibitors will be given a badge which must be worn in order to be admitted to the scientific sessions.

Badge is mandatory to enter the congress area.

A self-printing system will be available in the Registration Area. Delegates, sponsors and exhibitors will be able to collect their badges simply by having their personal barcode scanned by the optical reader at the self-printing machines.

Speakers are kindly requested to collect their badges at the Registration desk.

The QRcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.

CERTIFICATE OF ATTENDANCE

Delegates and speakers will be able to collect the certificate of attendance by having their personal QRcode read at the self-printing machines.

CLOAKROOM AND LUGGAGE

In the cloakroom you can leave your belongings free of charge.

The cloakroom is located in the Registration Area and will be open at the following hours:

Thursday, April 18, 2024	08.00 - 20.00
Friday, April 19, 2024	08.00 - 18.30
Saturday, April 20, 2024	08.00 - 16.00

TURIN INFORMATION DESK

For all information about the city (guided tours, museums, public transportation, etc.), please visit the Turin Information Desk. The desk is located at the entrance and it will be available as follows:

Thursday, April 18, 2024	12.00 - 16.00
Friday, April 19, 2024	12.00 - 16.00
Saturday, April 20, 2024	10.00 - 14.00

CATERING

Lunches, coffee breaks and the welcome cocktail are included in the registration fee.

You will be admitted showing your badges.

The EMN Welcome Cocktail is scheduled on Thursday, April 18, 2024 from 19.00 to 20.00 in the Catering Area.

The bar is located near the Exhibition Area and it will be open as follows:

Wednesday, April 17, 2024	08.00 – 19.00
Thursday, April 18, 2024	09.00 – 19.00
Friday, April 19, 2024	08.00 – 18.30
Saturday, April 20, 2024	08.00 – 18.00

AUDIO - VIDEO RECORDING

Audio-video recording is prohibited.

Only authorized staff can provide audio-video recording services.

EXHIBITION AREA

Access to the exhibition area will be as follows.

The exhibition area will be open at the following hours:

Thursday, April 18, 2024	09.00 - 20.00
Friday, April 19, 2024	09.00 – 18.30
Saturday, April 20, 2024	09.00 - 15.30

OFFICIAL WEBSITE

www.emn2024.com

APP

A special mobile app has been developed for this congress.

Use the app to find sessions of interest, create your own program, find and read all the abstracts.

Download the “EMN2024” app from Apple App store or Google Play.

SCIENTIFIC INFORMATION

LANGUAGE

The meeting will be in English with no simultaneous translation into other languages.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

Main program (April 18-19-20, 2024):

- Provider Studio ER Congressi SRL: ID 828- 410782.
- No. **4,2 CME** credits for **Physicians** (Clinical Biochemistry, Cardiac Surgery, Cardiology, General Surgery, Palliative Care, Haematology, Epidemiology, Pharmacology and Clinical Toxicology, Medical Genetics, Geriatrics, Laboratory of Medical Genetics, General Medicine Internal Medicine, Nuclear Medicine, Microbiology and Virology, Oncology, Clinica Pathology, Radiotherapy), **Biologists, Medical Laboratory Scientists, Nurses and Chemists.**
- Educational objective: "linee guida-protocolli-procedure".
- Meet the experts sessions, sponsored symposia are not included in the submission.

In order to claim for credits attendees should:

- attend at least the 90% of the submitted program;
- complete the CME forms. Please ask for it at the CME Registration Desk
- return the forms at the end of the meeting

EBAH CME CREDITS

The program of the "5th European Myeloma Network Meeting" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. **13 CME credits** for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

SLIDE CENTER/SPEAKERS'AREA

Opening hours:

Thursday, April 18, 2024	08.00 – 19.00
Friday, April 19, 2024	08.00 – 18.30
Saturday, April 20, 2024	08.00 – 15.00

POSTER AREA

Posters will be on display in the Poster Area for three days.

Posters should be installed/removed during the indicated set-up time:

Installation	Thursday, April 18, 2024	09.00 – 11.00
Tear off	Saturday, April 20, 2024	14.00 – 16.00

Materials to hang posters with will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors.

MEET THE EXPERT SESSIONS

Meet the Expert Sessions take place on April 18 and April 19, 2024 during the lunch break. Registration is free of charge but **spots are limited**. Preregistration to attend these sessions is necessary. If spots are still available, you can also register onsite during registration hours.

We suggest that you do this early in order to secure your spot.

ROOM	THURSDAY, APRIL 18, 2024 13.30 - 14.00	FRIDAY, APRIL 19, 2024 13.15 - 14.15
DUBLINO ROOM Ground floor	1 Managing the safety profile of CAR-T and bispecifics: can we safely treat elderly patients?	4 Monoclonal gammopathies of clinical significance
ATENE ROOM Ground floor	2 Stem cell collection in the era of quadruplets	5 PCL and EMD
PARIGI ROOM Mezzanine floor	3 Correlative studies	6 How to improve access to clinical trials

CHANGES

Parts of the program may be changed without prior notice.

FLOOR PLAN

EXHIBITION AREA

- 1-2 PFIZER
- 3-4 BRISTOL MYERS SQUIBB
- 6 BD BIOSCIENCES
- 7-8 MENARINI STEMLINE
- 9 SEBIA
- 12 BINDING SITE, PART OF THERMO FISHER SCIENTIFIC
- 13 SANOFI
- 14 JOHNSON AND JOHNSON
- 15 HEADS



PROGRAM

THURSDAY 18, APRIL 2024

09.25-09.30 **OPENING CEREMONY**

09.30-10.50 **SESSION I:**

MGUS AND SMM

Chairs: N. Bolli, I. Ghobrial

MGCS: diagnosis and treatment - **E. Kastritis**

SMM: risk stratification and management - **M.A. Dimopoulos**

SMM: to treat or not to treat? - **I. Ghobrial**

AUDITORIUM AGNELLI



B01

FUNCTIONAL DISSECTION OF THE SINGLE CELL TRANSCRIPTOMIC LANDSCAPE OF GENOTYPICALLY-IDENTIFIED POLYCLONAL PLASMACELLS IN MULTIPLE MYELOMA MICROENVIRONMENT

F. Lazzaroni, M.C. Da Vià, A. Matera, A. Marella, A. Maeda, A. Marchetti, S. Fabris, S. Pioggia, I. Silvestris, D. Ronchetti, S. Lonati, G. Fabbiano, V. Traini, E. Taiana, G. Castellano, C. De Magistris, M. Scopetti, N. Puccio, F. Torricelli, M. Barbieri, L. Pettine, A. Neri, M. Lionetti, F. Passamonti, N. Bolli (*Milan, Reggio Emilia-IT*)

B02

HIGH BODY MASS INDEX AND LOW AMOUNT OF IGM ARE ASSOCIATED TO MGUS PROGRESSION: A RETROSPECTIVE SINGLE-CENTER STUDY

A. Romano, A. Petronaci, N. Parrinello, S. Marino, G. Scuderi, D. Cambria, C. Botta, A. Neri, I. Dulcamare, V. Del Fabro, F. Di Raimondo, C. Conticello (*Catania, Palermo, Reggio Emilia-IT*)

Panel discussion

10.50-11.10 Coffee break and poster viewing

11.10-12.20 **SESSION II:**

RISK STRATIFICATION

Chairs: M.A. Dimopoulos, M. Kaiser

How to define HRMM in 2024 - **M. D'Agostino**

HR MM: beyond cytogenetics - **K.C. Weisel**

How to approach HRMM - **M. Kaiser**

AUDITORIUM AGNELLI



B03

ALTERATIONS IN EXPRESSION OF GENES CONTROLLING CELL SURFACE SIALYLATION IMPACT PROGNOSIS OF PATIENTS TREATED WITH CURRENT ANTI-MYELOMA THERAPIES

M. O'Dwyer, A. Ryan, S. Glavey, R. Mcaverra, B. Walker, C. Guerin-charbonnel, C. Bellanger, P. Moreau, C. Pellat-deceunynck, S. Minvielle (*Galway-IE, Dublin-IE, Indianapolis-USA, Nantes-FR*)

Panel discussion

12.20-13.30

SESSION III:

MRD IN CLINICAL TRIALS AND APPLICATION CHALLENGES IN CLINICAL PRACTICE

AUDITORIUM AGNELLI



Chairs: F. Gay, K. Yong

Imaging vs BM MRD: when and how? - **E. Zamagni**

The future of MRD testing in MM - **H. Jacobs**

MRD driven strategies: key ongoing and future trials - **E.A. Stadtmauer**

B04

PROSPECTIVE FUNCTIONAL BONE DISEASE EVALUATION OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH COMBINED USE OF 18F-FDG PET/CT AND WHOLE-BODY DIFFUSION WEIGHTED MAGNETIC RESONANCE

M. Talarico, G. De Cicco, P. Tacchetti, L. Pantani, K. Mancuso, C. Sartor, I. Rizzello, M. Iezza, F. Bigi, M. Puppi, I. Sacchetti, E. Manzato, S. Masci, R. Restuccia, S. Barbato, A. Cattabriga, S. Brocchi, C. Mosconi, C. Nanni, S. Fanti, M. Cavo, E. Zamagni (*Bologna-IT*)

Panel discussion - **E.K. Mai**

13.30-14.30

Lunch and meet the expert sessions on:

1. Managing the safety profile of CAR-T and bispecifics: can we safely treat elderly patients?

DUBLINO ROOM

M. Krauth, A. Larocca

2. Stem cell collection in the era of quadruplets

ATENE ROOM

A. Belotti, J. Radocha

3. Correlative studies

PARIGI ROOM

T. Cupedo, M. D'Agostino

14.30-15.30 **SESSION IV:**
NDMM - TRANSPLANT-INELIGIBLE PATIENTS
Chairs: S. Brinthen, K. Ramasamy
Treatment algorithm in transplant-ineligible patients - **S. Manier**
Tailoring treatment in frail patients: current knowledge
and future directions - **S. Brinthen**

AUDITORIUM AGNELLI



B05

A PROLONGED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN PLUS
LENALIDOMIDE AND DEXAMETHASONE SIGNIFICANTLY REDUCED OCULAR
ADVERSE EVENTS WITHOUT COMPROMISING CLINICAL ACTIVITY IN
TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA

E. Terpos, M. Gavriatopoulou, I. Ntanasis Stathopoulos, P. Malandrakis, D. Fotiou,
M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis Papaiakovou,
S. Gkolfinopoulos, G. Psarros, E. Kastritis, M.A. Dimopoulos (*Athens-GR, Dublin-IE*)

Panel discussion - **V. Montefusco**

15.30-15.50 **Coffee break and poster viewing**

15.50-18.50 **SPONSORED SESSIONS**
Details pag. 26

AUDITORIUM AGNELLI

19.00-20.00 **Welcome cocktail**

FRIDAY 19, APRIL 2024

09.00-09.45 **SESSION V:**
NDMM - TRANSPLANT-ELIGIBLE PATIENTS
Chairs: M. Cavo, X. Leleu
Treatment algorithm for TE patients - **P. Sonneveld**
Controversies in the management of TE patients - **X. Leleu**

Panel discussion

AUDITORIUM AGNELLI



09.45-10.50 **SESSION VI:**
RRMM PATIENTS
Chairs: R. Hajek, M. Mohty
Treatment algorithm at first relapses - **F. Gay**
New targets and novel combinations to treat RRMM:
beyond immunotherapy - **R. Popat**

AUDITORIUM AGNELLI



B06

DISSECTING THE MULTICELLULAR ECOSYSTEM IN EXTRAMEDULLARY
MYELOMA USING SPATIAL TRANSCRIPTOMICS

M. Helal, M. John, E. Stanojkovska, G. Mattavelli, L. Grundheber, A. Leipold,
N. Affrin, C. Riedhammer, J. Düll, J. Mersi, H. Einsele, K. Kretzschmar, M. Kortüm,
A. Riede, L. Rasche (*Würzburg-DE*)

B07

ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/
REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW-UP OF A
MULTICENTER, RETROSPECTIVE REAL-WORLD EXPERIENCE WITH 305 CASES
OUTSIDE OF CONTROLLED CLINICAL TRIALS

E.A. Martino, S. Palmieri, M. Galli, D. Derudas, R. Mina, R. Della Pepa, R. Zambello,
E. Vigna, A. Bruzzese, S. Mangiacavalli, E. Zamagni, C. Califano, M. Musso, C. Conticello,
C. Cerchione, G. Mele, N. Di Renzo, M. Offidani, G. Tarantini, G. Margiotta Casaluci,
A. Rago, R. Ria, G. Uccello, G. Barilà, G. Palumbo, L. Pettine, I.D. Vincelli, M. Brunori,
F. Accardi, V. Amico, A. Amendola, R. Fontana, V. Bongarzone, B. Rossini, E. Cotzia,
A. Gozzetti, R. Rizzi, N. Sgherza, G. Reddicono, A. Maroccia, L. Franceschini,
G. Bertuglia, D. Nappi, M.T. Petrucci, F. Di Raimondo, A. Neri, F. Morabito, P. Musto,
M. Gentile (*Cosenza, Napoli, Bergamo, Cagliari, Torino, Napoli, Padova, Pavia, Bologna,
Nocera-Pagani, Palermo, Catania, Meldola, Brindisi, Lecce, Ancona, Barletta, Novara,
Roma, Bari, Vicenza, Foggia, Milano, Reggio Calabria, Fano, Palermo, Benevento,
Potenza, Salerno, Augusta, Siena, Venezia Mestre, Reggio Emilia-IT*)

Panel discussion

10.50-11.15 Coffee break and poster viewing

11.15-12.15 **SESSION VII:
IMMUNOTHERAPY**

Chairs: H. Einsele, S.Z. Usmani

Immunotherapy for triple-class exposed MM - **A. Garfall**
Moving immunotherapy in early lines - **E.K. Mai**
Mechanisms of resistance to immunotherapy - **N. Bahlis**

Panel discussion

AUDITORIUM AGNELLI



12.15-13.15 **SESSION VIII:
BREAKTHROUGH TRIALS CHANGING
CLINICAL PRACTICE**

Chairs: M. Boccadoro, A. Spencer

Clinical studies for ND TE patients - **C. Touzeau**
Comments by **N. van de Donk**
Clinical studies for ND TE patients - **S. Zweegman**
Comments by **H. Mian**
Clinical studies for RRMM patients - **C. Driessen**
Comments by **R. Mina**

Panel discussion

AUDITORIUM AGNELLI



13.15-14.15 Lunch and meet the expert sessions on

4. Monoclonal gammopathies of clinical significance
N. Giuliani, P. Milani
5. PCL and EMD
G. Cengiz-Seval, P. Musto
6. How to improve access to clinical trials
A. Broijl, L. Rosinol

DUBLINO ROOM

ATENE ROOM

PARIGI ROOM

14.15-15.00 **SESSION IX:
HARMONY ALLIANCE: DATA-DRIVEN RESEARCH
IN MULTIPLE MYELOMA**

Chair: P. Sonneveld

- The HARMONY Alliance – EMN running projects - **E.K. Mai, A. Mosquera Orgueira**
- Opportunities in the utilization of synthetic data in Multiple Myeloma Research - **G. Castellani**
- HARMONY Alliance Foundation - **P. Sonneveld**

AUDITORIUM AGNELLI



15.00-15.30 Coffee break and poster viewing

15.30-18.30 **SPONSORED SESSIONS**

Details pag. 27

AUDITORIUM AGNELLI

SATURDAY 20, APRIL 2024

09.00-09.30 SPONSORED SESSION

Details pag. 27

AUDITORIUM AGNELLI

09.30-10.30 SESSION X: CHALLENGE SESSION - INNOVATION AND CHALLENGES IN MM

Chairs: I. Borrello, P. Neri

Artificial intelligence - A. Mosquera Orgueira

Comments by P. Neri

New immune and cellular therapy development/
in-house CAR-T model - C. Fernandez De Larrea

Comments by I. Borrello

How to improve access to immunotherapies
in the real-life setting - B. Bruno

Comments by J. Waldschmidt

Panel discussion

AUDITORIUM AGNELLI



12.40-13.20 SESSION XIII: RESHAPING THE FUTURE: THE TRIALS THAT WE NEED

Chairs: M. Boccadoro, P. Sonneveld

Young patients - C. Pawlyn

Elderly patients - R. Mina

Panel discussion - A.J. Jakubowiak

AUDITORIUM AGNELLI



13.20-14.00 Lunch and poster viewing

14.00-14.40 SESSION XIV: PATIENTS ASSOCIATIONS

Chairs: B. Durie, K. Joyner

IMF projects - B. Durie

MPE projects - K. Joyner

PRO - clinician perspective - K. Groen

Panel discussion

AUDITORIUM AGNELLI



10.30-11.25 SESSION XI: AMYLOIDOSIS

Chairs: G. Palladini, V. Santhorawala

Diagnosis - A. Dispenzieri

Therapeutic approach - S. Lentzsch

B08

FLORBETABEN PET IN AL AMYLOIDOSIS, A NEW PROMISING TECHNIQUE

R. Cassano, D. Genovesi, A. Giorgetti, G. Vergaro, A. Aimo, M.L. Del Giudice,
S. Galimberti, M. Edmin, G. Buda (Pisa-IT)

Panel discussion

AUDITORIUM AGNELLI



14.40-15.25 SESSION XV: TOXICITY OF IMMUNOTHERAPY

Chairs: M. Delforge, H. Ludwig

CRS icans cytopenia - T.S. Slørdahl

Infections and vaccination - E. Terpos

Panel discussion

AUDITORIUM AGNELLI



11.25-11.40 Coffee break and poster viewing

11.40-12.40 SESSION XII: EHA - EMN JOINT SESSION How to choose new treatment options for your patients

Chair: P. Sonneveld

CAR-T or bispecifics or ADCs - E. Zamagni

What to do after BCMA, CD38 and standard therapy? - M. Delforge

New guidelines for NDMM in 2024 - E. Terpos

Panel discussion

AUDITORIUM AGNELLI



15.25-15.30 CONCLUSIONS AND FINAL GREETINGS

AUDITORIUM AGNELLI

SPONSORED SYMPOSIA AND LECTURE

Thursday 18, April 2024

15.50-17.20 **BRISTOL MYERS SQUIBB
SPONSORED SYMPOSIUM** AUDITORIUM AGNELLI

**Navigating the myeloma treatment landscape:
cutting-edge insights in cellular therapies**

Chair: M. Cavo

Welcome and introduction - **M. Cavo**

Unmet needs in the era of novel therapies - **X. Leleu**

Treatment Choice for Triple-Class Exposed Patients in
Clinical Practice - **P. Rodríguez Otero**

Optimizing patient outcomes in triple-class exposed
patients with CAR-T Cell therapies - **M. Raab**

Panel discussion and summary close

17.20-18.50 **INDIPENDENT MEDICAL EDUCATIONAL SESSION
- UNCONDITIONAL SUPPORT BY GSK** AUDITORIUM
AGNELLI

New Challenges in elderly and frail RRMM

Chairs: M. Boccadoro, S. Zweegman

Impact of aging: focus on Frailty definition - **A. Larocca**

Practical considerations when approaching older patients - **C. Stege**

Balancing efficacy and toxicity - **C. Pawlyn**

Emerging challenges in RRMM - **R. Mina**

Case discussion: the journey of a frail patient - **H. Mian**

Panel discussion

Friday 19, April 2024

15.30-17.00 **JOHNSON & JOHNSON SPONSORED SYMPOSIUM** AUDITORIUM
AGNELLI

**Clinical trials and beyond: real-world experience
and patient experience of emerging agents in MM**

Chair: M. Mohty

Welcome and introduction - **M. Mohty**

Complementing clinical trials: Investigating the value of
real world evidence with insights from TE NDMM - **E. Zamagni**

Starting the treatment journey: Real world evidence for patients with
TIE NDMM and implications for sequencing - **S. Zweegman**

Engineering better outcomes: uncovering the emerging
real-world evidence base for T-cell redirecting therapies - **M. Delforge**

Panel discussion

17.00-18.30 **PER SYMPOSIUM** AUDITORIUM AGNELLI
- UNCONDITIONAL SUPPORT BY SANOFI

**New combination-based approaches to NDMM:
what do the data, the experts, and patients say?**

Chair: T. Facon

Welcome and introductions - **T. Facon**

Stratifying risk in newly diagnosed multiple myeloma (NDMM) - **F. Gay**

Survey.AI says: how patients feel and what they want
to know about NDMM - **T. Facon**

Evolving treatment paradigm for NDMM - **P. Sonneveld**

Q&A and conclusions - **T. Facon**

Saturday 20, April 2024

09.00-09.30 **MENARINI STEMLINE SPONSORED LECTURE** AUDITORIUM AGNELLI

Individualized treatment in early relapse for patients with relapsed and
refractory multiple myeloma (RRMM) - **E. Terpos, E. Zamagni**

ABSTRACT REVIEWERS

Meral	Beksac	Ankara, Turkey
Niccolò	Bolli	Milan, Italy
Annemiek	Broijl	Rotterdam, The Netherlands
Thomas	Cupedo	Rotterdam, The Netherlands
Mattia	D'Agostino	Turin, Italy
Martin	Kaiser	London, United Kingdom
Efstathios	Kastritis	Athens, Greece
Heinz	Ludwig	Wien, Austria
Roberto	Mina	Turin, Italy
Inger S.	Nijhof	Amsterdam, The Netherlands
Leo	Rasche	Würzburg, Germany
Fredrik Hellem	Schjesvold	Oslo, Norway
Cyrille	Touzeau	Nantes, France
Niels	van de Donk	Amsterdam, The Netherlands
Katja Christina	Weisel	Hamburg, Germany

POSTER

POSTER

1. BIOLOGY AND PRECLINICAL

P01

LIPID METABOLIC DYNAMICS CONVEYS RESISTANCE TO ANTI-BCMA IMMUNOTHERAPY IN MULTIPLE MYELOMA VIA FERROPTOSIS

E. La Spina, D. Tibullo, G. Scandura, S. Cortellino, C. Giallongo, L. Longhitano, S. Giallongo, I. Dulcamare, D. Cambria, M. Mecca, S. Picerno, A. Amoresano, G. Pinto, S. Serpico, A. Sgambato, F. Torricelli, N. Puccio, N. Parrinello, S. Marino, C. Conticello, C. Botta, A. Neri, F. Di Raimondo, A. Romano (Catania, Rionero in Vulture, Napoli, Roma, Reggio Emilia, Palermo-IT)

P02

SINGLE MASS SPECTROMETRY ASSAY TARGETTING M-PROTEIN, THERAPEUTIC ANTIBODIES, AND POLYCLONAL IMMUNOGLOBULINS PROVIDES UNIQUE INSIGHT INTO THERAPY RESPONSE KINETICS IN PATIENTS WITH MULTIPLE MYELOMA

C. Wijnands, P. Karel, J. Gloerich, V. Bonifay, L. Di Stefano, T. Luider, M. Vanduijn, A. Croockewit, E. De Kort, D. Castelijm, C. Stege, A. Van Gool, N. Van De Donk, J. Jacobs (Nijmegen-NL, Lisses-FR, Rotterdam-NL, Amsterdam-NL)

P03

ARGININE DEPRIVATION INDUCES DNA DAMAGE AND CHROMOSOMAL INSTABILITY: THE SEED AND SOIL IN MULTIPLE MYELOMA

G. Scandura, C. Giallongo, E. La Spina, I. Dulcamare, S. Giallongo, T. Zuppelli, L. Longhitano, A. Sbriglione, N. Vicario, D. Cambria, F. Torricelli, N. Puccio, Xin Hjaltelin, M. Herrera, N. Parrinello, V. Del Fabro, C. Conticello, C. Botta, D. Tibullo, G.A. Palumbo, Brunak, A. Neri, F. Di Raimondo, A. Romano (Catania, Palermo, Reggio Emilia-IT, Copenhagen-DK)

P04

EMN PROSPECTIVE SAMPLE COLLECTION PROJECT (EMN36): AN INTERNATIONAL UNIFORM SAMPLE REPOSITORY FOR PATIENTS WITH PLASMA CELL DYSCRASIAS TO ENABLE CORRELATIVE RESEARCH

M. D'agostino, R. Hájek, G.M. Casaluci, M. Offidani, P. Kessler, J. Minarik, L. Pengue, A. Belotti, P. Mikula, L. Stejskal, C. Terragna, L. Broskevičová, D. Oddolo, C. Driessen, M.T. Krauth, J. Bila, M. Delforge, E. Terpos, L.B. Leypoldt, S. Zweegman, Y.S. Choi, B. Bruno, A. Spencer, P. Sonneveld, M. Boccadoro, M. Van Duin (Torino, Ostrava-CZ, Novara-IT, Ancona-IT, Pelhrimov-CZ, Olomouc-CZ, Florence-IT, Brescia-IT, Havířov-CZ, Opava-CZ, Bologna-IT, Italy-IT, St. Gallen-CH, Vienna-AT, Belgrade-RS, Leuven-BE, Athens-GR, Hamburg-DE, Amsterdam-NL, Suwon-KR, Melbourne-AUS, Rotterdam-NL)

P05

NOVEL PROXIMITY LABELLING ASSAY FOR MONITORING DYNAMIC INTERACTIONS BETWEEN MULTIPLE MYELOMA AND CAR T-CELLS

T. Sevcikova, Q.N. Nguyen, V. Kapustova, P. Celichowski, O. Venglar, D. Zihala, T. Jelinek, R. Hajek, M. Simicek (Ostrava-CZ)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P06

ISATUXIMAB-CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE AS PRE-TRANSPLANT INDUCTION AND POST-TRANSPLANT CONSOLIDATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS OF THE PHASE III RANDOMIZED EMN24 ISKIA TRIAL

A. Broijl, W. Roeloffzen, M. A. Dimopoulos, L. Rosiñol, M. Van Der Klift, G. Bertuglia, A. Oriol Rocafiguera, E. Katodritou, K.L. Wu, P. Rodriguez Otero, R. Hájek, S. Mangiacavalli, M. Van Duin, M. D'agostino, E. De Waal, E. Ocio, M.D. Levin, M.V. Mateos, M. Grasso, P. Ypma, S.D.P.W.M. De Jonge-Peeters, T.S. Slørdahl, F. Schjesvold, J. Bladé, H. Einsele, P. Sonneveld, M. Boccadoro, F. Gay (Rotterdam-NL, Groningen-NL, Athens-GR, Barcelona-ES, Breda-NL, Torino-IT, Thessaloniki-GR, Antwerp-BE, Pamplona-ES, Ostrava-CZ, Pavia-IT, Leeuwarden-NL, Santander-ES, Dordrecht-NL, Salamanca-ES, Cuneo-IT, Den Haag-NL, Nijmegen-NL, Trondheim-NO, Oslo-NO, Würzburg-DE)

P07

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN NEWLY DIAGNOSED FIT OR INTERMEDIATE-FIT MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION: ANALYSIS OF SUSTAINED UNDETECTABLE MINIMAL RESIDUAL DISEASE (MRD) IN THE PHASE III EMN20 TRIAL

M. D'agostino, E. Antonioli, B. Gamberi, B. Bruno, D. Derudas, P. Tosi, F. Fazio, C. Carlo-Stella, S. Ronconi, V. Marasco, S. Ballanti, C. Cellini, A.P. Falcone, M. Offidani, P. Stefanoni, D. Rota-scalabrini, A. Agazzi, G. Margiotta Casaluci, G. Pietrantuono, F. Patriarca, A. Larocca, M. Boccadoro, S. Bringhen (Torino, Florence, Reggio Emilia, Cagliari, Rimini, Rome, Rozzano, Meldola, Milan, Perugia, Ravenna, San Giovanni Rotondo, Ancona, Bergamo, Candiolo, Novara, Rionero in Vulture, Udine-IT)

P08

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB (DARA) + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) VERSUS VRD ALONE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WHO ARE ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): PRIMARY RESULTS OF THE PERSEUS TRIAL

P. Sonneveld, M.A. Dimopoulos, M. Boccadoro, H. Quach, P.J. Ho, M. Beksac, C. Hulín, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I.S. Nijhof, N.W.C.J. Van De Donk, E. Katodritou, F. Schjesvold, A.S. Balari, L. Rosiñol, M. Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, R. Hájek, A. Jurczyszyn, S. Lonergan, T. Ahmadi, Y. Liu, J. Wang, D. Vieyra, E.M.J. Van Brummelen, V. Vanquickenberghe, A. Sitthi-Amorn, C.J. De Boer, R. Carson, P. Rodriguez-Otero, J. Bladé, P. Moreau (Rotterdam, Athens, Torino, Melbourne, Camperdown, Ankara, Pessac, Florence, Poitiers, Pavia, Toulouse, Bologna, Brescia, Amsterdam, Thessaloniki, Oslo, Barcelona, Leuven, Groningen, St. Gallen, Copenhagen, Würzburg, Melbourne, Ostrava, Kraków, Plainsboro, Beijing, Spring House, Leiden, Beerse, Pamplona, Nantes)

P09

IBERDOMIDE MAINTENANCE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FIRST RESULTS OF THE PHASE 2 EMN26 STUDY

N.W.C.J. Van De Donk, C. Touzeau, E. Terpos, A. Perrot, R. Mina, M. De Ruijter, E. Antonioli, E. Katodritou, N. Pescosta, P.A.F. Geerts, C. Sonntag, R. Wester, A. Belotti, S. Mangiacavalli, M. Offidani, M. D'agostino, M. Van Duin, M. Cavo, S. Aquino, A.M. Liberati, M.D. Levin, C. Hulin, M. Boccadoro, P. Sonneveld, F. Gay (Amsterdam-NL, Nantes-FR, Athens-GR, Toulouse-FR, Torino, Florence, Thessaloniki-GR, Bolzano, Zwolle-NL, Strasbourg-FR, Rotterdam-NL, Brescia, Pavia, Ancona, Bologna, Genova, Terni-PG, Dordrecht-NL, Bordeaux-FR)

P10

ENHANCED DETECTION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA THROUGH CD138 ENRICHMENT

P. Tabares, L. Scheller, K. Schmiedgen, J. Dhanraj, H. Dagdeviren, S. Sunuwar, A. Wilnit, M. Ulbrich, J. Waldschmidt, B. Paiva, K.M. Kortüm, L. Rasche, H. Einsele, A. Beilhack (Würzburg-DE, Pamplona-ES)

P11

EARLY RESULTS OF TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER DARATUMUMAB VTD INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

C. Liberatore, E. Rossi, L. Malerba, F. Fioritoni, F. Di Landro, F. Fazio, S. Ferraro, G. Antolino, L. De Padua, U. Coppetelli, V. Bongarzone, S. Pulini, P. Chiusolo, D. Vaddinelli, A. Natale, G. Visani, V. De Stefano, M. Di Ianni (Pescara, Rome, Pesaro, Frosinone, Latina, Chieti-IT)

P12

MOBILISATION OF HEMATOPOIETIC STEM CELLS WITH G-CSF BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DVRD VERSUS DVTD

M.K. Appelman, C. Fokkema, M. Grootes, R. Wester, E. De Pater, P. Sonneveld, A. Broijl (Rotterdam-NL)

P13

PROGNOSTIC IMPACT OF T(11;14) IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA

I. Ntanasis-Stathopoulos, E. Terpos, A. Briasoulis, P. Malandrakis, D. Fotiou, M. Migkou, V. Spiliopoulou, F. Theodorakakou, M. Roussou, N. Kanellias, E. Eleutherakis-Papaiaikovou, E. Kastritis, M.A. Dimopoulos, M. Gavriatopoulou (Athens-GR)

P14

IMMUNE CELL LANDSCAPE WITHIN THE BONE MARROW: A ROADMAP FROM MGUS TO ACTIVE MULTIPLE MYELOMA AND TREATMENT RESPONSIVENESS

A.M. Corsale, M. Shekarkar Azgomi, E. Gigliotta, M. Di Simone, A. Rizzuto, F. Garofalo, M. Speciale, M. Sciortino, C. Aquilina, A. Romano, F. Brucato, G. Corsale, D. Cambria, A. Neri, F. Buffa, N. Caccamo, F. Dieli, S. Meraviglia, S. Siragusa, C. Botta (Palermo, Catania, Reggio Emilia-IT)

P15

EXPLORING CLINICAL FEATURES THAT COULD PREDICT FUNCTIONAL HIGH RISK MULTIPLE MYELOMA PATIENTS: A REAL-WORLD ANALYSIS

S. Morè, L. Corvatta, V.M. Manieri, E. Morsia, M. Offidani (Ancona, Fabriano-IT)

P16

EFFICACY AND SAFETY OF IDECABTAGENE VICLEUCEL (IDE-CEL) WITH LENALIDOMIDE (LEN) MAINTENANCE VERSUS LEN MAINTENANCE ALONE IN ADULT PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WHO HAVE SUBOPTIMAL RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): PHASE 3 KarMMa-9 TRIAL

M. Mateos, A. Cohen, S. Harrison, S. Kumar, A. Perrot, F. Schjesvold, H. Einsele, P. Rodríguez-Otero, I. Abrahamsen, C. Fernandez de Larrea, R. Schots, V. Kivovich, F. Wu, X. Zhong, T. Finocchio, M. Popa Mckiver, M. Cook, N. Raje (Salamanca-ES, Philadelphia-USA, Melbourne-AUS, Rochester-USA, Toulouse-FR, Würzburg-DE, Pamplona-ES, Oslo-NO, Barcelona-ES, Brussels-BE, Cambridge-USA, Princeton-USA, Boudry-CH, Boston-USA)

P18

REAL-WORLD DATA WITH LENALIDOMIDE AS MAINTENANCE THERAPY FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: THE EXPERIENCE OF THE "RETE EMATOLOGICA PUGLIESE" (REP)

N. Di Renzo, N.M. Dargenio, N. Sgherza, P.V. Federico, M.P. Fina, R. Matera, P. Curci, R. Rizzi, G. Tarantini, C. Germano, M.P. Falcone, N. Cascavilla, A.M. Carella, L. Melillo, G. Palumbo, B. Rossini, A. Guarini, A. Rana, V. Pavone, A. Mele, R. De Francesco, D. Pastore, G. Mele, F. Merchionne, G. Specchia, P. Musto (Lecce, Bari, Barletta, San Giovanni Rotondo, Foggia, Tricase, Brindisi-IT)

P19

IMPACT OF DARATUMUMAB ON HEMATOPOIETIC STEM CELL MOBILIZATION WITH G-CSF AND ON-DEMAND PLERIXAFOR IN NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS

B. Garibaldi, G. Bertuglia, A. Casson, B. Sarina, F. Gay, S. Mercadante, I. Mariotti, M. D'agostino, D. Taurino, S. Oliva, A. Larocca, D. Mannina, C. Dephilippis, G. Benevolo, T. Francisci, M. Lorenzi, B. Bruno, A. Santoro, S. Bringhen, S. Bramanti, R. Mina (Milan, Turin-IT)

P20

EFFICACY AND SAFETY OF DARATUMUMAB-BASED COMBINATION THERAPIES IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-LIFE POPULATION ANALYSIS ACCORDING TO IMWG FRAILTY SCORE

A. Belotti, C. Crippa, R. Daffini, R. Ribolla, S. Ferrari, A. Peli, A. Tucci (Brescia-IT)

P21

IDENTIFICATION OF CLINICAL-BIOLOGICAL FEATURES OF NEWLY DIAGNOSED EARLY RELAPSE MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

L. Cillo, B. Dalla Palma, S. Ricci, M. Pedrazzoni, M. Scita, M. Bernardi, G. Sammarelli, L. Pelagatti, N. Giuliani (Parma-IT)

P22

HIGH RATE OF RESPIRATORY TRACT INFECTIONS AFTER COVID19 WAVES IN TRANSPLANT ELEGIBLE MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB

F. Farina, V. Ferla, L. Canziani, R. Dell'Acqua, T. Perini, D. Clerici, D. Sannipoli, S. Markt, S. Mastaglio, R. Greco, M.T. Lupo-Stanghellini, M. Bernardi, I. Peccatori, C. Corti, M. Marcatti, F. Ciceri (*Milan-IT*)

P23

IMPACT OF DARATUMUMAB, BORTEZOMIB, THALIDOMIDE DEXAMETHASONE INDUCTION THERAPY ON STEM CELL MOBILIZATION: A REAL WORLD EXPERIENCE

F. Accardi, M. Porrazzo, G. Sapienza, R. Bono, S. Tringali, C. Rotolo, C. Botta, A. Santoro, L. Di Noto, L. Castagna, C. Patti (*Palermo-IT*)

P24

PROGNOSTIC PROFILING OF PATIENTS WITH MULTIPLE MYELOMA: REAL WORLD APPLICABILITY

A. Sretenovic, M. Mitrovic, N. Vukosavljevic, Z. Bukumiric, N. Kecman, M. Todorovic, J. Jovanovic, J. Bila (*Belgrade-RS*)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P25

TALQUETAMAB + POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SAFETY AND PRELIMINARY EFFICACY RESULTS FROM THE PHASE 1B MONUMENTAL-2 STUDY

J. Matous, N. Biran, A. Perrot, J.G. Berdeja, K. Dorritie, C. Van Elssen, E. Searle, C. Touzeau, S. Anguille, D. Vishwamitra, A. Nguyen, D. Ghosh, E. Shearin, K. Thornton, M.D. Smit, H. Quach (*Denver-USA, Hackensack-USA, Toulouse-FR, Nashville-USA, Pittsburgh-USA, Maastricht-NE, Manchester-UK, Nantes-FR, Edegem-BE, Spring House-USA, Bridgewater-US, Leiden-NL, Melbourne-AUS*)

P26

EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1-3 PRIOR LINES WHO RECEIVED CILTACABTAGENE AUTOLEUCEL AS STUDY TREATMENT CARTITUDE-4 TRIAL (PHASE 3)

M.H. Sidiqi, P. Corradini, D. Purtill, H. Einsele, B. Dhakal, L. Karlin, S. Manier, S. Iida, S. Giebel, S.J. Harrison, B. Lipe, A.M. Khan, J.M. Schechter, C.C. Jackson, T. Yeh, A. Banerjee, W. Deraedt, N. Lendvai, C. Lonardi, A. Slaughter, K. Li, D. Chen, J. Gilbert, T. Roccia, M. Zhao, N. Patel, E. Florendo, M. Koneru, O. Costa Filho, D. Geng, J. San-miguel, K. Yong (*Perth-AUS, Bentley-AUS, Milan-IT, Würzburg-DE, Milwaukee-USA, Pierre-Bénite-FR, Lille-FR, Nagoya-JP, Gliwice-PL, Melbourne-AUS, Parkville-AUS, Rochester-USA, Columbus-USA, Raritan-USA, Spring House-USA, Beerse-BE, Buenos Aires-AR, Zug-CH, Shanghai-CN, High Wycombe-UK, Raritan-USA, Shanghai-CN, Somerset-USA, Somerset-USA, Pamplona-ES, London-UK*)

P27

EFFICACY AND SAFETY OF LESS FREQUENT/LOWER INTENSITY DOSING OF TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

A. Chari, A. Oriol, A. Krishnan, C. Martinez-Chamorro, L. Costa, M.V. Mateos, M. Minnema, M. Campagna, T.J. Masterson, B. Hilder, J. Tolbert, T. Renaud, M.D. Smit, S. Ramanjulu, P. Rodriguez-Otero (*New York-USA, Barcelona-ES, Duarte-USA, Madrid-ES, Birmingham-USA, Salamanca-ES, Utrecht-NE, Madrid-ES, Spring House-USA, Raritan-USA, Leiden-NE, Pamplona-ES*)

P28

UPDATED RESULTS OF TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH PRIOR EXPOSURE TO T-CELL REDIRECTING THERAPIES: RESULTS OF THE PHASE 1/2 MONUMENTAL-1 STUDY

A. Jakubowiak, S. Anguille, L. Karlin, A. Chari, C. Schinke, L. Rasche, J. San-Miguel, M. Campagna, B.W. Hilder, T. Masterson, X. Qin, T. Renaud, J. Tolbert, D. Vishwamitra, S. Skerget, P. Moreau (*Chicago-USA, Edegem-BE, Pierre-Bénite-FR, New York-USA, Little Rock-USA, Würzburg-DE, Pamplona-ES, Madrid-ES, Spring House-USA, Raritan-USA, Nantes-FR*)

P29

CARTITUDE-4 STUDY (PHASE 3) PATIENT-REPORTED OUTCOMES OF CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AFTER 1-3 LINES OF THERAPY

R. Mina, A.K. Mylin, H. Yokoyama, H. Magen, W. Alsdorf, M.C. Minnema, L. Shune, I. Isufi, S.J. Harrison, U.A. Shah, J.M. Schechter, N. Lendvai, K.S. Gries, E.G. Katz, A. Slaughter, C. Lonardi, J. Gilbert, Q. Li, W. Deraedt, O. Costa Filho, N. Patel, L. Karlin, K. Weisel (*Turin-IT, Copenhagen-DK, Sendai-JP, Tel Aviv-IL, Hamburg-DE, Utrecht-NL, Kansas City-USA, New Haven-USA, Melbourne-AUS, Parkville-AUS, New York-USA, Raritan-USA, Raritan-USA, Zug-CE, Buenos Aires-AR, High Wycombe-UK, Apex-USA, Beerse-BE, Somerset-USA, Pierre-Bénite-FR*)

P30

PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1-3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)

J. Hillengass, A.D. Cohen, M.E. Agha, M. Delforge, T. Kerre, W. Roeloffzen, H. Einsele, H. Goldschmidt, K. Weisel, M.S. Raab, C. Scheid, S. Anguille, P. Sonneveld, S. Zweegman, J.M. Schechter, K.C. De Braganca, C.C. Jackson, P. Vlummens, H. Varsos, C. Corsale, D. Madduri, T. Yeh, P. Mistry, T. Roccia, Q. Song, M. Akram, O. Costa Filho, D. Geng, Y.C. Cohen, N.W.C.J. Van De Donk (*Buffalo-USA, Philadelphia-USA, Pittsburgh-USA, Leuven-BE, Ghent-BE, Groningen-NL, Würzburg-DE, Heidelberg-DE, Hamburg-DE, Heidelberg-DE, Cologne-DE, Edegem-BE, Rotterdam-NL, Amsterdam-NL, Raritan-USA, Beerse-BE, High Wycombe-UK, Raritan-USA, Somerset-USA, Tel Aviv-IL*)

P31

LOCOMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – FINAL ANALYSIS AT 2-YEAR FOLLOW-UP

P. Moreau, K. Weisel, V. De Stefano, H. Goldschmidt, M. Delforge, M. Mohty, J. Lindsey-Hill, D. Dytfeld, E. Angelucci, L. Vincent, A. Perrot, R. Benjamin, N.W.C.J. Van De Donk, E.M. Ocio, E. In't Groen-Damen, T. Rocca, J.M. Schechter, I. Haddad, V. Strulev, L. Mitchell, J. Buyze, S. Saarinen, O. Costa Filho, H. Einsele, M.V. Mateos (Nantes-FR, Hamburg-DE, Rome-IT, Heidelberg-DE, Leuven-BE, Paris-FR, Nottingham-UK, Poznań-PL, Genova-IT, Montpellier-FR, Toulouse-FR, London-UK, Amsterdam-NL, Santander-ES, Breda-NL, Raritan-USA, Raritan-USA, Issy-les-Moulineaux-FR, Beerse-BE, Allschwil-CH, Espoo-FI, Somerset-USA, Würzburg-DE, Salamanca-ES)

P32

IMPACT OF COVID-19 ON OUTCOMES WITH TECLISTAMAB IN THE PHASE 1/2 MAJESTEC-1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

N.W.C.J. Van De Donk, N. Bahlis, L.J. Costa, M.V. Mateos, A. Nooka, A. Perrot, P. Thaman, K. Qi, C. Uhlar, K. Chastain, M. Doyle, S.Z. Usmani (Amsterdam-NL, Calgary-CA, Birmingham-USA, Salamanca-ES, Atlanta-USA, Toulouse-FR, Bridgewater-USA, Titusville-USA, Spring House-USA, Raritan-USA, Dublin-IE, New York-USA)

P33

TREATMENT OUTCOMES OF TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED BY APPROACHING TARGETABLE MUTATIONS

G. Cengiz Seval, I. Kuzu, S. Yuksel, G. Kaygusuz, K. Dalva, M. Ozcan, M. Beksac (Ankara-TR)

P34

LONG-TERM OUTCOMES FROM THE PHASE 3 OCEAN (OP-103) STUDY: MELFLUFEN AND DEXAMETHASONE (DEX) VERSUS POMALIDOMIDE (POM) AND DEX IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

F. Schjesvold, M.A. Dimopoulos, S. Delimpasi, P. Robak, D. Coriu, W. Legieć, L. Pour, I. Špička, T. Masszi, V. Doronin, J. Minarik, G. Salogub, Y. Alexeeva, A. Lazzaro, V. Maisnar, G. Mikala, S. Norin, M. Thuresson, A. Bergan, J. Obermüller, R. Hájek, M.V. Mateos, P.G. Richardson, P. Sonneveld (Oslo-NO, Athens-GR, Łódź-PL, Bucharest-RO, Lublin-PL, Brno-CZ, Prague-CZ, Moscow-RU, Olomouc-CZ, St. Petersburg-RU, Piacenza-IT, Hradec Králové-CZ, Budapest-HU, Stockholm-SE, Ostrava-CZ, Salamanca-ES, Boston-USA, Rotterdam-NL)

P35

OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY DISEASE IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION + MOMMENT STUDIES

P. Moreau, M.V. Mateos, H. Goldschmidt, M.E. Gonzalez Garcia, B. Besemer, M.S. Gonzalez Perez, M. Mohty, J. Lindsey-hill, S. Kirkpatrick, M. Delforge, E. Angelucci, F. Di Raimondo, R. Vij, M. Doyle, K. Gray, C. Albrecht, V. Strulev, I. Haddad, S. Koskinen, L. Mitchell, J. Buyze, K. Weisel (Nantes-FR, Salamanca-ES, Heidelberg-DE, Gijón-ES, Tuebingen-DE, Santiago de Compostela-ES, Paris-FR, Nottingham-UK, Bristol-UK, Leuven-BE, Genova-IT, Catania-IT, Saint Louis-USA, Dublin-IE, Bridgewater-USA, Issy-les-Moulineaux-FR, Beerse-BE, Espoo-FI, Allschwil-CH, Hamburg-DE)

P36

MECHANISMS OF RESISTANCE AND RELAPSE WITH TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

D. Vishwamitra, S. Skerget, D. Cortes, O. Lau, C. Davis, T. Renaud, J. Tolbert, B.W. Hilder, T.J. Masterson, M. Campagna, C. Heuck, A. Chari, N.W.C.J. Van De Donk, R. Verona (Spring House-USA, Raritan-USA, Madrid-ES, New York-USA, Amsterdam-NE)

P37

LONGITUDINAL CORRELATIVE PROFILES OF RESPONDERS, NONRESPONDERS, AND THOSE WITH RELAPSE ON TREATMENT WITH TECLISTAMAB IN THE PHASE 1/2 MAJESTEC-1 STUDY OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA LONGITUDINAL CORRELATIVE PROFILES OF RESPONDERS, NONRESPONDERS, AND THOSE WITH RELAPSE ON TREATMENT WITH TECLISTAMAB IN THE PHASE 1/2 MAJESTEC-1 STUDY OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

D. Vishwamitra, S. Skerget, D. Cortes, T. Perova, O. Lau, C. Davis, Y. Guo, X. Miao, T. Stephenson, C. Hodin, C. Uhlar, D. Trancucci, K. Chastain, N. Bahlis, N.W.C.J. Van De Donk, R. Verona (Spring House-USA, Antwerp-BE, Raritan-USA, Calgary-CA, Amsterdam-NL)

P38

PRELIMINARY RECOMMENDATIONS FOR PREVENTION AND MANAGEMENT OF INFECTIONS, HYPOGAMMAGLOBULINEMIA, AND NEUTROPENIA DURING TREATMENT WITH TECLISTAMAB BASED ON EXPERIENCE FROM THE MAJESTEC-1 STUDY

N.W.C.J. Van De Donk, A.K. Nooka, C. Rodriguez, M.V. Mateos, K. Chastain, A. Banerjee, R. Kobos, K. Qi, R. Verona, M. Doyle, T.G. Martin, S. Manier (Amsterdam-NL, Atlanta-USA, New York-USA, Salamanca-ES, Raritan-USA, Spring House-USA, Titusville-USA, Dublin-IE, San Francisco-USA, Lille-FR)

P39

CLINICAL OUTCOMES OF SUBSEQUENT THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING TALQUETAMAB TREATMENT: ANALYSES FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

L. Sanchez, C. Schinke, A. Krishnan, J. Berdeja, N.W.C.J. Van De Donk, M.V. Mateos, A. Chari, S. Parekh, T. Mouhieddine, S. Jagannath, N. Bahlis, C. Touzeau, A. Oriol, J. San-Miguel, P. Rodríguez-Otero, M.C. Minnema, M. Campagna, T.J. Masterson, B. Hilder, J. Tolbert, T. Renaud, K. Gray, M. Damiette Smit, C. Heuck, L. Rasche (New York-USA, Little Rock-USA, Duarte-USA, Nashville-USA, Amsterdam-NL, Salamanca-ES, New York-USA, Calgary-CA, Nante-FR, Barcelona-ES, Pamplona-ES, Utrecht-NL, Madrid-ES, Spring House-USA, Raritan-USA, Horsham-USA, Leiden-NL, Würzburg-DE)

P40

PRACTICAL CONSIDERATIONS ON MANAGEMENT OF INFECTION IN PATIENTS RECEIVING BISPECIFIC ANTIBODIES: A SINGLE CENTER EXPERIENCE

V. Del Fabro, C. Pennisi, S. Leotta, A. Petronaci, L. Longo, F. Elia, F. Di Raimondo, C. Conticello (Catania)

P41

THE RISING UNMET NEED FOR MULTIPLE MYELOMA PATIENTS AFTER FIRST-LINE TREATMENT WITH DRd: AN EPIDEMIOLOGICAL ESTIMATE IN ITALY BETWEEN 2024-2028

F. Fiorentino, M. Boccadoro, R. Mercati, C. Vassallo, B. Canali, C. Galeone (Milan, Turin-IT)

4. SPECIAL CONDITIONS

P42

EFFICACY AND SAFETY OF DARATUMUMAB (DARA) MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): FINAL ANALYSIS OF THE PHASE 2 CENTAURUS STUDY

O. Landgren, A. Chari, Y.C. Cohen, A. Spencer, P.M. Voorhees, I. Sandhu, M.W. Jenner, D. Smith, M. Cavo, N.W.C.J. Van De Donk, M. Beksac, P. Moreau, H. Goldschmidt, L. Sha, L. Li, E. Rousseau, R. Dennis, R. Carson, C.C. Hofmeister (Miami-USA, New York-USA, Tel Aviv-IL, Melbourne-AUS, Charlotte-USA, Edmonton-CA, Southampton-UK, Nottinghamshire-UK, Bologna-IT, Amsterdam-NL, Ankara-TR, Nantes-FR, Heidelberg-DE, Shanghai-CN, Beerse-BE, Raritan-USA, Spring House-USA, Atlanta-USA)

P43

CLINICAL OUTCOME OF LATENT TUBERCULOSIS INFECTION DETECTED BY QUANTIFERON-TB TEST IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING NOVEL DRUGS: FOCUS ON REACTIVATION PROPHYLAXIS IN A RETROSPECTIVE, SINGLE-CENTER STUDY

N. Sgherza, P. Curci, A. Capozzi, G. Di Carlo, D. Grande, G. Brindicci, A. Russo Rossi, P. Musto (Bari-IT)

P44

BURDEN OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA AND SECONDARY IMMUNODEFICIENCIES: A RETROSPECTIVE COHORT STUDY

J. Richter, C. Anderson-Smits, K. Ren, M. Kamieniak, D. Shah, C. Siffel (New York-USA, Lexington-USA, Cambridge-USA)

P45

POOLED ANALYSIS OF SAFETY FROM BIRTAMIMAB PHASE 1-3 TRIALS IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS

V. Santhorawala, A. Wechalekar, E. Kastritis, G. Palladini, S. Schönland, R. Comenzo, A. D'Souza, J. Khouri, V. Jimenez-Zepeda, K.I. Sprinz, H. Hao, W. Huang, L. Governale Aubrey, M. Gertz (Boston-USA, London-UK, Athens-GR, Pavia-IT, Heidelberg-DE, Boston-USA, Milwaukee-USA, Cleveland-USA, Calgary-CA, Brisbane-USA, Rochester-USA)

P46

DARATUMUMAB-BASED REGIMENS FOR PATIENTS WITH MULTIPLE MYELOMA PLUS EXTRAMEDULLARY PLASMACYTOMAS OR PARASKELETAL PLASMACYTOMAS: INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE

G. Mele, D. Derudas, C. Conticello, G. Barilà, M. Gentile, S. Rocco, S. Palmieri, G. Palazzo, C. Germano, G. Reddiconto, N. Sgherza, D. De Novellis, C. Galeone, S. Agavni' Castiglioni, L. Deiana, A. Pascarella, E.A. Martino, I. Foggetti, I. Blasi, A. Spina, M. Urbano, M.L. Di Noi, F. Merchionne, C. Schifone, N. Di Renzo, A. Maggi, G. Tarantini, F. Di Raimondo, G. Specchia, P. Musto, D. Pastore (Brindisi, Cagliari, Catania, Vicenza, Mestre-Venezia, Cosenza, Napoli, Taranto, Barletta, Lecce, Bari, Salerno, Milano, Padova-IT)

P47

LIGHT-CHAIN (AL) AMYLOIDOSIS IN THE REAL-WORLD SETTINGS

M. Mitrovic, A. Sretenovic, Z. Bukumiric, M. Todorovic Balint, M. Perunicic Jovanovic, R. Maksimovic, D. Sobic Saranovic, S. Radojevic Skodric, A. Ristic, J. Bila (Belgrade-RS)

P48

ANTIBODY RESPONSE TO BREAKTHROUGH SARS-COV-2 INFECTION IN "BOOSTER" VACCINATED PATIENTS WITH MULTIPLE MYELOMA ACCORDING TO B, T AND NK LYMPHOCYTE ABSOLUTE COUNTS AND ANTI-CD38 TREATMENTS

N. Sgherza, A. Mestice, A.M.V. Larocca, P. Musto (Bari-IT)

P49

REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY DISEASE

A.G. Szabo, S. Sánchez-Ramón, C. Siffel, C. Anderson-Smits, B. Mccoy, M. Kamieniak (Copenhagen-DK, Madrid-ES, Cambridge-USA, Vienna-AT)

ACKNOWLEDGEMENTS

With an unrestricted educational grant of

PLATINUM SPONSOR



Johnson & Johnson

sanofi

GOLD SPONSOR



Stemline
A Menarini Group Company

SILVER SPONSOR

AMGEN

heads



REGENERON
SCIENCE TO MEDICINE

CONTRIBUTORS

BD Biosciences

Binding Site
part of Thermo Fisher Scientific

Sebia

5th European Myeloma Network Meeting



MEETING VENUE

Lingotto Conference Center

Via Nizza, 280 - 10126 Turin - Italy

Ph +39.011.6311702

www.centrocongressilingotto.it

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld (*The Netherlands*) - EMN President

Mario Boccadoro (*Italy*) - EMN Vicepresident

Francesca Gay (*Italy*)

Roberto Mina (*Italy*)

Niels van de Donk (*The Netherlands*)

Sonja Zweegman (*The Netherlands*)

THE EMN BOARD

Pieter Sonneveld (*The Netherlands*)

Mario Boccadoro (*Italy*)

Meral Beksac (*Turkey*)

Gordon Cook (*UK*)

Meletios Athanasios Dimopoulos (*Greece*)

Christoph Driessen (*Switzerland*)

Hermann Einsele (*Germany*)

Roman Hajek (*Czech Republic*)

Heinz Ludwig (*Austria*)

Philippe Moreau (*France*)

Jesus Fernando San-Miguel (*Spain*)

Fredrik Schjesvold (*Norway*)

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna - Italy

Ph +39 051 4210559

E-mail: emnmeeting@ercongressi.it

www.ercongressi.it

Turin

April 18-20, 2024

Lingotto Conference Center